Miscellaneous Neoplasm - Solid Tumor

NCT03213665

Clinical Trial Information


Trial Number: NCT03213665 (ClinicalTrials.gov)
Disease Type:
  • CNS Neoplasm (Primary Tumor) - Miscellaneous
  • CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex"
Study ID:
APEC1621C
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT06303167

Clinical Trial Information


Trial Number: NCT06303167 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
"MATCH Treatment Subprotocol E: Osimertinib (AZD9291) in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR"
Study ID:
EAY131-E
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT06351371

Clinical Trial Information


Trial Number: NCT06351371 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Hematopoietic Neoplasm/Myeloma - Myeloma
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients With Tumors With FGFR Mutations or Fusions
Study ID:
EAY131-K2
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT06308822

Clinical Trial Information


Trial Number: NCT06308822 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Hematopoietic Neoplasm/Myeloma - Myeloma
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients With Tumors With FGFR Amplifications
Study ID:
EAY131-K1
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT03213691

Clinical Trial Information


Trial Number: NCT03213691 (ClinicalTrials.gov)
Disease Type:
  • CNS Neoplasm (Primary Tumor) - Miscellaneous
  • CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Study ID:
APEC1621E
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439175

Clinical Trial Information


Trial Number: NCT04439175 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA mutation but without KRAS mutation or PTEN loss
Study ID:
EAY131-I
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439201

Clinical Trial Information


Trial Number: NCT04439201 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification
Study ID:
EAY131-Z1B
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439136

Clinical Trial Information


Trial Number: NCT04439136 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations
Study ID:
EAY131-B
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT03578081

Clinical Trial Information


Trial Number: NCT03578081 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
  • Miscellaneous Neoplasm - Carcinoma, Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
OLANZAPINE WITH OR WITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Study ID:
A221602
Images are available?:
No
Is this a NCI-MATCH Trial?:
No

NCT04439357

Clinical Trial Information


Trial Number: NCT04439357 (ClinicalTrials.gov)
Disease Type:
  • Hematopoietic Neoplasm/Lymphoma - Miscellaneous
  • Miscellaneous Neoplasm - Solid Tumor
Trial Title:
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 Mutations
Study ID:
EAY131-S2
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Subscribe to Miscellaneous Neoplasm - Solid Tumor

Accessibility  |  Disclaimer  |  FOIA  |  HHS Vulnerability Disclosure  |  Privacy & Security

U.S. Department of Health and Human Services  |  National Institutes of Health  |  National Cancer Institute  |  USA.gov

NIH…Turning Discovery Into Health®